Keaton S Smetana, Jacob Counts, Angad Sodhi, Casey C May
{"title":"Review of Target-Specific Anticoagulation Reversal Agents.","authors":"Keaton S Smetana, Jacob Counts, Angad Sodhi, Casey C May","doi":"10.1097/CNQ.0000000000000400","DOIUrl":null,"url":null,"abstract":"<p><p>Bleeding related to direct oral anticoagulants accounts for nearly half of emergency department visits annually and until recently there were no reversal antidotes available. As there continues to be a shift in prescribing practices away from warfarin, it is essential to have these reversal agents readily available for the treatment of life-threatening bleeds associated with these anticoagulants. In addition, for agents that continue to lack a targeted reversal agent (eg, low-molecular-weight heparin, antiplatelets, and new antithrombotics), it is imperative that research continues to evaluate improved reversal strategies. This review focuses on target-specific anticoagulation reversal agents currently available in the United States (protamine, idarucizumab, and andexanet alfa) and summarizes agents that are in the pipeline for these anticoagulants and antiplatelets.</p>","PeriodicalId":10789,"journal":{"name":"Critical Care Nursing Quarterly","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care Nursing Quarterly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CNQ.0000000000000400","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 2
Abstract
Bleeding related to direct oral anticoagulants accounts for nearly half of emergency department visits annually and until recently there were no reversal antidotes available. As there continues to be a shift in prescribing practices away from warfarin, it is essential to have these reversal agents readily available for the treatment of life-threatening bleeds associated with these anticoagulants. In addition, for agents that continue to lack a targeted reversal agent (eg, low-molecular-weight heparin, antiplatelets, and new antithrombotics), it is imperative that research continues to evaluate improved reversal strategies. This review focuses on target-specific anticoagulation reversal agents currently available in the United States (protamine, idarucizumab, and andexanet alfa) and summarizes agents that are in the pipeline for these anticoagulants and antiplatelets.
期刊介绍：
Critical Care Nursing Quarterly (CCNQ) is a peer-reviewed journal that provides current practice-oriented information for the continuing education and improved clinical practice of critical care professionals, including nurses, physicians, and allied health care professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
